Podcasts about Scd

An internationally recognized leader in air quality, epidemiology and exposure assessment, George Thurston, ScD, of New York University headlines this important episode analyzing the Lung Association's 2025 “State of the Air” report. With nearly half of the people living in the U.S. breathing unhealthy amounts of air pollution, Thurston delves into the acute and accumulative health impacts on communities across the country. Listen in to learn more about the report's key learnings, from adverse effects of exposure to ground-level ozone pollution to the decade-long worsening trend of particle pollution. Want more Lungcast? Visit us at HCPLive.com/podcasts/lungcast or www.lung.org/professional-education/lungcast

This week, Dr. Kahn explores the serious topic of sudden cardiac death (SCD)—a condition that claims roughly 1,500 lives per day in the U.S. alone. Survival rates remain low whether it occurs in or out of the hospital, but a new study highlights key risk factors everyone should know. One unexpected takeaway? Champagne might play a role. Plus, Dr. Kahn covers a few quick-hitting topics: advanced glycation end products (AGEs), the benefits of dietary potassium, and how even incidental physical activity can make a difference. Brought to you by www.endur.com — use code KahnMD10 at checkout to save.

La violoncellista y compositora Ángela Acuña busca integrar nuevamente el Consejo Directivo de la SCD, con una propuesta clara: abrir las puertas a los músicos emergentes y transparentar la gestión de derechos. En un escenario donde se cuestiona el rol de la institución, Acuña quiere que la SCD deje de ser temida y empiece a ser valorada. Hablamos sobre inclusión, diversidad musical y el salto digital que aún falta. ¿Está preparada la SCD para representar a todos los creadores?

This week we review a recent editorial commentary by Drs. Belinda Gray, Rachel Lampert and Michael Papadakis on the concept of the personalized emergency action plan for the patient with genetic heart disease who is 'returning to play' in vigorous sports. With newer data demonstrating that risk for SCA or SCD is perhaps not as high as was once thought in this setting of sport, can the development of a personalized emergency action plan further enhance safety beyond simple measures such as medical adherence? Who should be involved in drafting this emergency action plan and how does this feature in the concept of 'shared decision-making'? DOI: 10.1161/CIRCULATIONAHA.124.072830

Welcome to our new mini-series on research capacity strengthening, produced in partnership with the Centre for Capacity Research at the Liverpool School of Tropical Medicine. In this first episode, we explore the design of a Research Capacity Strengthening (RCS) component within an implementation research project, and why it is crucial for sustainable, patient-centred healthcare. Our conversation draws insights from those actively embedding RCS into their work, demonstrating how improving research skills and systems drives real impact in global health.In this episode:Dr. Justin Pulford - Reader at the Centre for Capacity Research, Liverpool School of Tropical Medicine.Dr. Justin Pulford is Deputy Head of the Centre for Capacity Research (CCR) at the Liverpool School of Tropical Medicine (LSTM). A behavioural scientist by training, he has extensive experience developing, implementing, and evaluating research and health systems strengthening initiatives across sub-Saharan Africa and the South Pacific. Dr Pulford also convenes the ‘TROP 703: Public Health Programmes, Policies and Strategies' module for LSTM's MPH programme. Professor Obiageli Nnodu - Co-lead of the PACTS programme, University of Abuja.Professor Obiageli Nnodu is Professor of Haematology and Blood Transfusion at the University of Abuja, Nigeria, and Director of its Centre of Excellence for Sickle Cell Disease Research and Training. She leads multiple NIH-funded sickle cell projects and chairs Africa's largest SCD network. Professor Nnodu also advises the Nigerian government on non-communicable diseases and serves on WHO AFRO committees dedicated to improving sickle cell care.Professor Alex Osei-Akoto - Kwame Nkrumah University of Science and Technology, GhanaProfessor Alex Osei-Akoto is Principal Investigator for PACTS in Ghana. A Professor of Child Health at Kwame Nkrumah University of Science and Technology (KNUST) and Consultant Paediatrician at Komfo Anokye Teaching Hospital, he has focused on sickle cell disease for over two decades. Professor Osei-Akoto led key newborn screening initiatives, advised Ghana's Ministry of Health on SCD, and co-authored numerous publications. He now spearheads PACTS implementation in Ghana, building on his extensive clinical and research leadership in paediatric haematology.Dr. Catherine Chunda-Liyoka - University of ZambiaDr. Catherine Chunda-Liyoka is Head of the Paediatric Haematology Department at Zambia's University Teaching Hospitals–Children's Hospital. She provides specialised care in sickle cell disease, haemophilia, aplastic anaemia, HIV, and TB, while leading multiple research initiatives. As an Honorary Lecturer at the University of Zambia and an Honorary Fellow at LSTM, she mentors health workers nationwide. Dr. Chunda-Liyoka also advises the Zambian Ministry of Health on paediatric haematology and infectious diseases, and plays a key role in major SCD networks—including SPARCO and PACTS—to strengthen national guidelines and clinical practices.Useful linksCentre for Capacity Research | LSTMPatient-centred sickle cell disease management in sub-Saharan Africa (PACTS) | LSTMWant to hear more podcasts like this?Follow Connecting Citizens to Science on your usual podcast platform or YouTube to hear more about current research and debates within global health.The podcast cuts across disciplines, including health systems strengthening, gender and intersectionality, tropical diseases (NTDs, TB, Malaria), maternal and child healthcare (antenatal and postnatal care), mental...

You said yes to implementing a watershed project. Now what? From start to finish what is the step-by-step process? What resources are available to support SCD?- Join Hannah Nordby, Emilee Novak and Chance Porsborg for Part 2 of Implementing a Watershed Project!-Go ahead grab a cup of joe and settle in as we converse about serving, preserving, and conserving across the Great Plains, you don't want to miss out!-Emilee NovakNPS Program CoordinatorWatershed Management Program701-328-5240  ⁠ejnovak@nd.gov

John M. Lachin, ScD, Biostatistics Center, George Washington University, discusses Nonparametric Statistical Analysis with JAMA Statistical Editor Roger J. Lewis, MD, PhD. Related Content: Nonparametric Statistical Analysis

Today, we share our five top stocks to buy if they won thelottery, including picks like Pernod Ricard, Visa, Ferrari, Microsoft, and LVMH. With no restrictions, such as yield, we look at key factors driving our choices, such as brand power, growth potential, and pricing strength.We also preview an upcoming newsletter on big pharma, with Derek focusing on Merck & Co. and the top-selling drug, Kuda.And as always, we finish with some excellent Listener questions

Send us a textThe quest for better outcomes in pediatric IBD has taken significant strides forward, and Dr. Jeremy Adler returns to Bowel Moments to guide us through the most promising research developments of the past year. Dr. Adler is a clinical Professor in the Division of Pediatric Gastroenterology at the University of Michigan and serves as the Interim Director of the Susan B. Meister Child Health Evaluation and Research (CHEAR) Center. We discuss how medication dosing strategies have evolved dramatically, with compelling evidence showing that body surface area measurements work better than traditional weight-based dosing for younger children. This seemingly simple adjustment yields dramatically better results, particularly as children grow and develop through puberty. Regular therapeutic drug monitoring—checking medication levels every 6-12 months or more frequently during growth spurts—has also proven critical for maintaining disease control in the pediatric population.Prevention emerges as the cornerstone of Dr. Adler's research and clinical philosophy. The fascinating GEM study has identified changes in gut permeability that occur before IBD diagnosis, potentially opening doors to early intervention before symptoms appear. Meanwhile, Dr. Adler's own groundbreaking research demonstrates that early, aggressive treatment with anti-TNF medications can prevent serious complications like perianal fistulas, fistulas, and abscesses—complications that significantly impact quality of life and body image.We navigate the complex terrain of treatment barriers, from insurance denials to psychological resistance to "stronger" medications. Dr. Adler challenges common misconceptions, noting that injectable or infusion medications often have better safety profiles than some oral options that patients perceive as "less intense." The conversation turns to normalizing surgical options like ostomies when needed, with Dr. Adler advocating for early introduction to surgical teams—not because surgery is imminent, but because establishing relationships reduces trauma if intervention becomes necessary.With new medication mechanisms emerging and genetic markers helping to personalize treatment approaches, the research landscape offers real hope for children with IBD. Join us for this candid, informative discussion about protecting children from the worst outcomes of IBD through early intervention, personalized treatment, and collaborative care models that address both physical and mental wellbeing.Links: Research article- Preventing Fistulas and Strictures Among Children with Crohn's DiseaseJournal Article referenced- National Perspectives of Barriers by Insurance and Pharmacy Benefits Managers in Pediatric Inflammatory Bowel DiseaseImproveCareNowLet's get social!!Follow us on Instagram!Follow us on Facebook!Follow us on Twitter!

Gene therapy offers significant hope for treating sickle cell disease (SCD), a genetic disorder caused by a single mutation in the hemoglobin gene. Recent advancements have led to promising developments and FDA approvals, but challenges remain. In this podcast episode, gene therapy survivor, Jimi Olaghere, shares his journey and offers hope to others with his inspirational message and through his advocacy for patients in the sickle cell community.

Artificial intelligence (AI) in health care is advancing, despite concerns about how its use may impact health disparities. Dimitri Christakis, MD, MPH, chief health officer at Special Olympics, joins JAMA Associate Editor Yulin Hswen, ScD, MPH, to discuss AI's potential role in improving health care delivery for people with intellectual and developmental disabilities. Related Content: How AI Could Improve Health Care for People With Intellectual and Developmental Disabilities How Artificial Intelligence Can Promote Inclusive Health

Sickle cell anaemia is a disease of red blood cells, caused by an autosomal recessive single gene defect in the beta-chain of haemoglobin, which results in production of sickle cell haemoglobin. Sickle cells can obstruct blood flow and break down prematurely, and they are associated with varying degrees of anaemia. A common presentation of sickle cell disease (SCD) is a painful sickle crisis, caused by obstruction of small blood capillaries. Treatment includes symptom control (including pain management) and prevention and management of complications. Until now, haematopoietic stem-cell transplantation has been the only potentially curative treatment option, but a new type of gene therapy has just been launched by NHS England. In this episode, Dr Roger Henderson gives an overview of some of the key points of SCD, with a focus on this new treatment and its availability.Access episode show notes containing key references and take-home points at:https://gpnotebook.com/en-GB/podcasts/haematology/ep-148-sickle-cell-disease.Did you know? With GPnotebook Pro, you can earn CPD credits by tracking the podcast episodes you listen to. Learn more.

In this video on research published in JACC and presented at ACC.25, Yuan Lu, ScD, JACC: Executive Associate Editor, discusses her study on optimal blood pressure management for adults aged 80 and above. Her study found that systolic blood pressure below 130 mmHg is associated with lower cardiovascular risk, while levels above 145 mmHg increase heart-related mortality. The study supports intensive blood pressure management but emphasizes the need for personalized treatment and further research on long-term effects and potential risks.#jacc #jaccjournals #acc25

A recent study showed AI-assisted screening using a large language model tool reduced time to determine trial eligibility compared with manual methods. Author Alexander J. Blood, MD, MSc, cardiologist at Brigham and Women's Hospital, and Associate Director of the Accelerator for Clinical Transformation Research Group at Harvard Medical School joins JAMA Associate Editor Yulin Hswen, ScD, MPH, to discuss this topic and more. Related Content: Study Finds AI Can Quickly Prescreen Patients for Clinical Trials, Speeding Enrollment Manual vs AI-Assisted Prescreening for Trial Eligibility Using Large Language Models—A Randomized Clinical Trial

AI can play a role in addressing language barriers in health care. In a recent Editorial in JAMA Network Open, Pilar Ortega, MD, MGM, of the University of Illinois College of Medicine, and coauthors emphasized the urgent need for integrating language equity into digital health solutions. Dr Ortega joins JAMA and JAMA+ AI Associate Editor Yulin Hswen, ScD, MPH, to discuss. Related Content: Researcher Proposes New Framework for Language Equity in Health Technology Language Equity in Health Technology for Patients With Non–English Language Preference Challenges to Video Visits for Patients With Non–English Language Preference

On this week's episode, Josh Schimmer,  Yaron Werber, Brian Skorney, Tess Cameron, and Eric Schmidt kick off the show covering the macro news of the week including the new FTC head and what it means for M&A in the industry. The group also discusses how the biopharma industry is not challenging RFK Jr., the BioSecure Act missing from the Defense Bill and Luigi Mangione's arrest. In ASH Conference highlights, the hosts recap the CAR-T battle of Arcellx/Gilead vs Ligand/J&J, as well as updates from Agios and other SCD cell therapies. Other topics discussed include Blenrep's return, BTK degraders from Beigene and Nurix, the Revance/Crown deal as well the big stock movers off the week. This episode aired on December 13, 2024.

Lung ultrasound aids in the diagnosis of patients with dyspnea but requires technical proficiency for image acquisition. Cristiana Baloescu, MD, MPH, of Yale School of Medicine, joins JAMA Associate Editor Yulin Hswen, ScD, MPH, to discuss a new study published in JAMA Cardiology evaluating the ability of AI to guide acquisition of diagnostic-quality lung ultrasound images by trained health care professionals. Related Content: AI-Guided Lung Ultrasounds Could Help Nonexpert Clinicians Acquire “Expert-Level” Images Artificial Intelligence–Guided Lung Ultrasound by Nonexperts

A recent study in JAMA Network Open evaluates the use of machine learning algorithms to assess the management of urinary tract infection (UTI). Author Sanjat Kanjilal, MD, MPH, professor in the Department of Population Medicine at Harvard Medical School and Harvard Pilgrim Healthcare Institute, joins JAMA Associate Editor Yulin Hswen, ScD, MPH, to discuss this topic and more. Related Content: Researchers Use Machine Learning to Put Older Clinical Guidelines to the Test Use of Machine Learning to Assess the Management of Uncomplicated Urinary Tract Infection

How have perspectives of psychiatric rehabilitation shifted over time? Join us as we speak with Dr. Marianne Farkas, ScD, a clinical professor at Boston University and one of the founding members of the Center for Psychiatric Rehabilitation. Dr. Farkas explain four major shifts in mental health rehabilitation that have taken place, in addition to various global perspectives on mental health and the importance of person-centered care. Tune in for this informative and impactful episode!

With accelerating global adoption of AI, countries are developing ethical AI frameworks to prevent harm to the most vulnerable populations. Maria Villalobos-Quesada, PhD, from the University of Barcelona, discusses this and more with JAMA+ AI Associate Editor Yulin Hswen, ScD, MPH. Related Content: Study Finds Limited Evidence to Support More Than 40 Predictive Machine Learning Algorithms Used in Primary Care Availability of Evidence for Predictive Machine Learning Algorithms in Primary Care The Need for Continuous Evaluation of Artificial Intelligence Prediction Algorithms

American Indian and Alaska Native communities have higher rates of suicide than any other racial or ethnic group in the US. A recent study published in JAMA Network Open describes an AI-based suicide screening tool investigated in an American Indian community. Author Emily Haroz, PhD, of Johns Hopkins Bloomberg School of Public Health, joins JAMA and JAMA+ AI Associate Editor Yulin Hswen, ScD, MPH. Related Content: How AI Could Help Clinicians Identify American Indian Patients at Risk for Suicide Performance of Machine Learning Suicide Risk Models in an American Indian Population

Jacqueline Fawcett, RN; PhD; ScD (hon); FAAN; ANEF Dr. Fawcett received her Bachelor of Science degree from Boston University in 1964, her Master of Arts degree in Parent Child Nursing […]

Chatbots may have a role in enhancing clinical care, but the best way to apply them remains a work in progress. Jonathen Chen, MD, PhD, and Ethan Goh, MD, MS, of Stanford, join JAMA and JAMA+ AI Associate Editor Yulin Hswen, ScD, MPH, to discuss their randomized clinical trial published in JAMA Network Open investigating the use of chatbots in clinical practice. Related Content: An AI Chatbot Outperformed Physicians and Physicians Plus AI in a Trial—What Does That Mean? Large Language Model Influence on Diagnostic Reasoning

Imagine being 15 years old but having a body that shows signs of aging as if you are decades older. For some young people with sickle cell disease (SCD), this is a reality. A new study published in Volume 16, Issue 21 of Aging shows that SCD causes the body to age much faster than normal. The research not only explains why this happens but also points to new ways to help people with the disease live healthier, longer lives. What Is Sickle Cell Disease? SCD is a genetic condition that changes the shape of red blood cells. Instead of being round, like a doughnut, the cells become curved like a sickle (a farming tool). These misshapen cells struggle to move through blood vessels, often blocking blood flow and leading to pain, organ damage, and other health problems. Even with modern treatments, they can experience complications like those seen in older adults, such as weaker bones, frailty, and organ failure. In the study “Adolescents and young adults with sickle cell disease exhibit accelerated aging with elevated T-cell p16INK4a expression,” researchers wanted to understand why this happens and what it means for people with the disease. Full blog - https://aging-us.org/?p=6372 Paper DOI - https://doi.org/10.18632/aging.206152 Corresponding author - Samuel R. Wilson - samuel.wilson@med.unc.edu Video short - https://www.youtube.com/watch?v=QXVdxBikaqg Sign up for free Altmetric alerts about this article - https://aging.altmetric.com/details/email_updates?id=10.18632%2Faging.206152 Subscribe for free publication alerts from Aging - https://www.aging-us.com/subscribe-to-toc-alerts Keywords - aging, sickle cell disease, p16, adolescents, young adults About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​ and connect with us: Facebook - https://www.facebook.com/AgingUS/ X - https://twitter.com/AgingJrnl Instagram - https://www.instagram.com/agingjrnl/ YouTube - https://www.youtube.com/@AgingJournal LinkedIn - https://www.linkedin.com/company/aging/ Pinterest - https://www.pinterest.com/AgingUS/ Spotify - https://open.spotify.com/show/1X4HQQgegjReaf6Mozn6Mc MEDIA@IMPACTJOURNALS.COM

My guest today is Dr. Kristen Lyall, ScD. Dr. Lyall received a Doctor of Science in Epidemiology from Harvard School of Public Health. During her postdoctoral training, she received training in Nutrient Science at Harvard and Pediatric Epidemiology at UC-Davis MIND Institute's Autism Research Training Program. Currently, Dr. Lyall is an Associate Professor at Drexel University's A.J. Drexel Autism Institute – Modifiable Risk Factors Program.The overarching goal of the Modifiable Risk Factors program is to identify factors that can be changed to prevent or mitigate the adverse effects associated with Autism, thereby potentially improving outcomes for individuals and informing public health policy and practice. Dr. Lyall's expertise provides actionable tools for listeners to understand the environmental risks of Autism. By the end of the episode, we hope you gain insight into the identified modifiable risk factors for Autism.Dr. Kristen Lyall: https://drexel.edu/autisminstitute/about/our-team/all-staff/Kristen-Lyall/Dr. Lyall publications link: https://pubmed.ncbi.nlm.nih.gov/?term=Kristen%20Lyall&sort=pubdateECHO: https://echochildren.orgFish not Supplements: https://echochildren.org/research-summaries/fish-but-not-supplements-consumed-in-pregnancy-associated-with-lower-rates-of-autism-diagnosis-and-related-traits-echo-cohort-study-finds/Other Resources:Biological Energy: Quantum Mechanisms, Water, DHA, and NF-kB (Autism is a loss of energy- electrons, photons, protons)https://youtu.be/2-IA_gunXbw0:00 Dr. Kristen Lyall2:30 Her Journey into Epidemiology & Autism7:50 The Role of Epidemiology & Autism12:15 Modifiable Risk Factors17:32 Dietary Influences on Autism Risk; Eat more FISH (DHA!)22:53 Assessing Exposure & Risk Factors32:35 Immune & Hormonal Factors in Autism; Cytokines & Inflammation39:17 The Impact of Acute Events during Pregnancy44:45 Air Pollution & its Effects in Neurodevelopment; Oxidative Stress48:14 Current & Future Research; ECHO & EARLI56:34 Reviews/Ratings, Contact InfoX: https://x.com/rps47586YouTube: https://www.youtube.com/channel/UCGxEzLKXkjppo3nqmpXpzuAHopp: https://www.hopp.bio/fromthespectrumemail: info.fromthespectrum@gmail.com

Do you dread annual performance reviews? Do you avoid providing honest feedback when an employee isn't meeting job expectations? You aren't alone, affective performance reviews don't just happen, they take intentional effort. - Join Jason Sutheimer an HR guru with over 20 years of experience and Area V Program Coordinator, Hannah Nordby as they converse about how conducting empowering performance reviews that allows your SCD to focus on serving, preserving, and conserving across the Great Plain- AND beyond! - ND HR Resources: Society for Human Resource Management (SHRM – global coverage): www.shrm.org North Dakota Society for Human Resource Management (ND SHRM – ND coverage): https://ndshrm.com/   Central Dakota Human Resource Association (CDHRA – Bismarck & has a presence in Minot & Williston): https://cdhra.shrm.org/home Fargo-Moorhead Human Resource Association (FMHRA – Fargo): https://www.fmhra.com/ Greater Grand Forks Human Resource Association (GGFHRA – Grand Forks & has a presence in Devils Lake): https://ggfhra.wildapricot.org/Board-Members Southwest Area Human Resource Association (SAHRA – Dickinson): https://ndsahra.shrm.org/

In this week's episode, unravelling follicular lymphoma subtypes. Researchers dissect the biological diversity of follicular lymphoma and introduce a new prognostic mode, that could change the way this B-cell neoplasm is subtyped and treated. Then, concerning stroke rate trends in sickle cell disease. A new report shows increasing rates of cerebrovascular events among people with SCD in California. Finally, procoagulant platelet activation promotes venous thrombosis. Investigators report finding procoagulant platelets in the circulation and in thrombi of patients and mice with DVT or PE. Featured Articles:Follicular lymphoma comprises germinal center–like and memory-like molecular subtypes with prognostic significanceRates of strokes in Californians with sickle cell disease in the post-STOP eraProcoagulant platelet activation promotes venous thrombosis

Sickle cell disease (SCD) is a condition of immense and multifarious clinical gravity causing acute pain, joint damage, anemia and risk of infection, stroke, delayed growth in children and adolescents — as well as long-term organ dysfunction. However, recent evolutions in treatment options offer promising novel and emerging therapeutics poised to truly revolutionize SCD care. On this episode of NP Pulse: The Voice of the Nurse Practitioner®, nurse practitioner (NP) specialists Sheryl Mitchell and Artangela Henry guide NPs to achieve the following learning objectives: Describe the epidemiologic patterns, pathophysiologic principles and robust patient burden of SCD. Examine current best practices for SCD diagnosis, highlighting the fundamental importance of early disease detection, characterization and linkage to treatment. Evaluate the established and evolving therapeutic landscape for SCD, with a focus on recent regulatory approvals and emerging trial data for novel agents. Design individualized, evidence-driven treatment plans for patients with SCD that mitigate disease complications and improve quality of life. Identify residual unmet needs in the SCD treatment paradigm and discuss the role of ongoing research and comprehensive, multidisciplinary care strategies in closing these gaps. This program and the accompanying clinical resource tool were made possible by a medical education grant from Vertex. Continuing education (CE) credit for this program may be claimed through Dec. 31, 2025. To claim credit for this program, log in to the CE Center, search for this program by name and complete the post-test and evaluation by entering the participation code Sickle24.

BUFFALO, NY- December 11, 2024 – A new #research paper was #published in Aging (listed by MEDLINE/PubMed as "Aging (Albany NY)" and "Aging-US" by Web of Science) Volume 16, Issue 21 on November 14, 2024, entitled, “Adolescents and young adults with sickle cell disease exhibit accelerated aging with elevated T-cell p16INK4a expression.” Researchers Samuel R. Wilson, Natalia Mitin, Vanessa L. Ayer Miller, Andrew B. Smitherman, and Marcus A. Carden, from the University of North Carolina at Chapel Hill, Sapere Bio, Campbell University, and Cogent Biosciences have discovered that young people with sickle cell disease (SCD) exhibit signs of accelerated biological aging compared to those without the disease. By measuring levels of p16INK4a, a key marker of cellular aging, the team found significantly higher levels in individuals with SCD. Remarkably, some participants showed biological aging equivalent to an additional 43 years. These findings suggest that SCD may drive faster aging in the body, offering new insights into the disease's long-term impact. Sickle cell disease (SCD) is a genetic condition primarily affecting individuals of African or Mediterranean descent. While treatments have advanced, people with SCD often face significant health challenges, including complications that mimic the effects of aging. Cellular aging, or senescence, occurs when cells stop dividing yet continue to send harmful signals that damage surrounding tissues. Researchers believe this process happens at an accelerated rate in people with SCD, underscoring the importance of finding ways to slow it down and mitigate its impact. The study compared p16INK4a levels in 18 adolescents and young adults with SCD to 27 healthy people of the same age. The results showed that even the youngest participant with SCD had higher levels of this aging marker than anyone in the non-SCD group. “Our youngest participant, a 15-year-old with SCD, had a higher p16 expression than all the comparators, underscoring the early rise of p16 expression in this population.” The researchers believe this faster aging could be caused by the chronic inflammation, lack of oxygen, and stress on the body associated with SCD. Along with managing the symptoms of the disease, SCD patients also face a higher risk of aging-related problems like organ damage and physical decline much earlier in life. The findings suggest that measuring p16INK4a levels could help clinicians identify patients at risk for these problems earlier and offer targeted care. The study also opens the door to new treatments, such as drugs that aim to remove old, damaged cells. These therapies could potentially slow down the aging process. Further research is essential to confirm these findings and to gain a deeper understanding of how to support SCD patients effectively. Larger, long-term studies could investigate whether therapies targeting cell aging can help prevent complications and improve the quality of life for individuals with SCD. In conclusion, this study marks an important step in understanding how SCD accelerates aging and offers new ways to improve the lives of those living with the condition. DOI - https://doi.org/10.18632/aging.206152 Corresponding author - Samuel R. Wilson - samuel.wilson@med.unc.edu Video short - https://www.youtube.com/watch?v=QXVdxBikaqg About Aging-US The mission of the journal is to understand the mechanisms surrounding aging and age-related diseases, including cancer as the main cause of death in the modern aged population. The journal aims to promote 1) treatment of age-related diseases by slowing down aging, 2) validation of anti-aging drugs by treating age-related diseases, and 3) prevention of cancer by inhibiting aging. (Cancer and COVID-19 are age-related diseases.) Please visit our website at https://www.Aging-US.com​​. MEDIA@IMPACTJOURNALS.COM

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.The FDA's accelerated approval pathway, established in 1992, has allowed over 200 new drugs to come to market based on surrogate endpoints. While many products have later received full FDA approval, recent withdrawals like Pfizer's Oxbryta and Takeda's Exkivity have raised concerns about the risks of this pathway. Despite some high-profile failures, the program has a strong track record, with over half of accelerated approvals converting to full approval. The pathway has been used primarily for cancer treatments but is now expanding to other disease areas like neurological and rare diseases. Recent failures of confirmatory trials for drugs like Sarepta's Elevidys have prompted experts to call for tighter timelines and better biomarkers for surrogate endpoints in order to improve the program. The future of the accelerated approval pathway is under scrutiny, with questions arising about how often it should be used and what areas it should focus on next.AbbVie's Tavapadon showed improvement in motor and daily living complications in a Phase III trial, following the failure of another key cerevel asset, Emraclidine. Relmada Therapeutics is considering strategic alternatives, including a potential sale, after halting two Phase III trials for a major depressive disorder drug. Other news includes BioAge discontinuing a Phase II obesity study, Merck's promising anti-ROR1 ADC data for lymphoma treatment, and Novo and Catalent's $16.5 billion deal receiving EU approval. Additionally, Vertex and Beam report advances in SCD cell and gene therapies, while evidence grows for the potential of GLP-1s in Alzheimer's disease.Recent studies have shown that GLP-1 receptor agonists, commonly used for weight loss and diabetes, may have potential in treating Alzheimer's disease. Phase III results from Novo Nordisk are expected next year. Additionally, amylin analogs are emerging as a potential alternative or complement to GLP-1 receptor agonists for weight loss with a cleaner tolerability profile. Other news includes a weight loss victory claimed by Lilly over Novo in a head-to-head study, FDA action alerts, and promising cancer therapies from companies like AstraZeneca and Merus. The FDA is also investigating the safety of Bluebird's gene therapy Skysona for hematologic malignancies. Applied Therapeutics recently faced a crash after FDA rejection of a rare disease drug. Overall, the potential of GLP-1s in Alzheimer's disease and the emergence of amylin analogs in weight loss are significant developments in the biopharma industry.

Effective communication is essential in medicine, yet language barriers can result in suboptimal care. AI holds promise for bridging these gaps, enhancing outcomes, and reducing disparities. Casey Lion, MD, MPH, from the University of Washington School of Medicine, joins JAMA and JAMA+ AI Associate Editor Yulin Hswen, ScD, MPH, to discuss AI as an interpreter in the clinic. Related Content: Researcher Explores Using AI to Overcome Language Barriers With Patients Artificial Intelligence for Language Translation

In this special episode on Root Causes of Obesity, Sugar and Highly Processed Carbs,  our host, Dr. Neil Skolnik will discuss Root Causes of Obesity, Sugar, and Strategies to Decrease Sugar in the Diet with three experts in field – a nutrition epidemiologist, a public health expert and a registered dietician. This special episode is supported by an independent educational grant from Heartland Food Group, the maker of the Splenda Group of Products.  For more information just go to: www.splenda.com . Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Vasanti Malik, ScD, who is Assistant Professor and Canada Research Chair in Nutrition and Chronic Disease Prevention, Department of Nutritional Sciences, University of Toronto Sandra Albrecht, PhD, Assistant Professor, Department of Epidemiology and Co-lead, Food Systems and Public Health Certificate Program, Columbia University Mailman School of Public Health.    Marina Chaparro, RDN, CDCES, MPH who is a Registered Dietitian and a Certified Diabetes Educator & Author

A recent JAMA Cardiology essay argues that medicine is not just a technical endeavor, it's also a moral endeavor, and a robot does not have moral agency. Coauthor Sarah C. Hull, MD, MBE, of Yale School of Medicine, joins JAMA and JAMA+ AI Associate Editor Yulin Hswen, ScD, MPH, to discuss the use of AI in managing decision-making in cardiac care. Related Content: AI Can't Worry About Patients, and a Clinical Ethicist Says That Matters Echoes of Concern—AI and Moral Agency in Medicine

The following question refers to Sections 7.3.3 and 7.3.6 of the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure.The question is asked by Palisades Medical Center medicine resident & CardioNerds Academy Fellow Dr. Maryam Barkhordarian, answered first by UTSW AHFT Cardiologist & CardioNerds FIT Ambassador Dr. Natalie Tapaskar, and then by expert faculty Dr. Robert Mentz.Dr. Mentz is associate professor of medicine and section chief for Heart Failure at Duke University, a clinical researcher at the Duke Clinical Research Institute, and editor-in-chief of the Journal of Cardiac Failure. Dr. Mentz has been a mentor for the CardioNerds Clinical Trials Network as lead principal investigator for PARAGLIDE-HF and is a series mentor for this very Decipher the Guidelines Series. For these reasons and many more, he was awarded the Master CardioNerd Award during ACC22.The Decipher the Guidelines: 2022 AHA / ACC / HFSA Guideline for The Management of Heart Failure series was developed by the CardioNerds and created in collaboration with the American Heart Association and the Heart Failure Society of America. It was created by 30 trainees spanning college through advanced fellowship under the leadership of CardioNerds Cofounders Dr. Amit Goyal and Dr. Dan Ambinder, with mentorship from Dr. Anu Lala, Dr. Robert Mentz, and Dr. Nancy Sweitzer. We thank Dr. Judy Bezanson and Dr. Elliott Antman for tremendous guidance.Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. American Heart Association's Scientific Sessions 2024As heard in this episode, the American Heart Association's Scientific Sessions 2024 is coming up November 16-18 in Chicago, Illinois at McCormick Place Convention Center. Come a day early for Pre-Sessions Symposia, Early Career content, QCOR programming and the International Symposium on November 15. It's a special year you won't want to miss for the premier event for advancements in cardiovascular science and medicine as AHA celebrates its 100th birthday. Registration is now open, secure your spot here!When registering, use code NERDS and if you're among the first 20 to sign up, you'll receive a free 1-year AHA Professional Membership! Question #39 Ms. Kay Lotsa is a 48-year-old woman with a history of CKD stage 2 (baseline creatinine ~1.2 mg/dL) & type 2 diabetes mellitus. She has recently noticed progressively reduced exercise tolerance, leg swelling, and trouble lying flat. This prompted a hospital admission with a new diagnosis of decompensated heart failure. A transthoracic echocardiogram reveals LVEF of 35%. Ms. Lotsa is diuresed to euvolemia, and she is started on carvedilol 25mg BID, sacubitril/valsartan 49-51mg BID, and empagliflozin 10mg daily, which she tolerates well. Her eGFR is at her baseline of 55 mL/min/1.73 m2 and serum potassium concentration is 3.9 mEq/L. Your team is anticipating she will be discharged home in the next one to two days and wants to start spironolactone. Which of the following is most important regarding her treatment with mineralocorticoid antagonists?ASpironolactone is contraindicated based on her level of renal impairment and should not be startedBSerum potassium levels and kidney function should be assessed within 1-2 weeks of starting spironolactoneCEplerenone confers a higher risk of gynecomastia than does spironolactoneDThe patient will likely not benefit from initiation of spironolactone if her cardiomyopathy is ischemic in origin Answer #39 ExplanationThe correct answer is B – after starting a mineralocorticoid receptor antagonist (MRA), it is important to closely monitor renal function and serum potassium levels.MRA (also known as aldosterone antagonists or anti-mineralocorticoids) show consistent improvements in all-cause mortality, HF hospitalizations, and SCD across a wide range of patients with HFrEF.

It's Medicare open enrollment season, and in this episode first aired in 2021, we explain why shopping for a new plan is often tougher than it seems.Guests:Lilyan Grossman, Medicare beneficiaryTricia Neuman, ScD, Senior Vice President and Executive Director of the Program on Medicare Policy, Kaiser Family FoundationAmal Trivedi, MD, Professor of Medicine and Health Services, Policy, and Practice, Brown UniversityLearn more and read a full transcript on our website.Want more Tradeoffs? Sign up for our free weekly newsletter featuring the latest health policy research and news.Support this type of journalism today, with a gift. Hosted on Acast. See acast.com/privacy for more information.

The following question refers to Section 7.4 of the 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure.The question is asked by the Director of the CardioNerds Internship Dr. Akiva Rosenzveig, answered first by Vanderbilt AHFT cardiology fellow Dr. Jenna Skowronski, and then by expert faculty Dr. Clyde Yancy.Dr. Yancy is Professor of Medicine and Medical Social Sciences, Chief of Cardiology, and Vice Dean for Diversity and Inclusion at Northwestern University, and a member of the ACC/AHA Joint Committee on Clinical Practice Guidelines.The Decipher the Guidelines: 2022 AHA / ACC / HFSA Guideline for The Management of Heart Failure series was developed by the CardioNerds and created in collaboration with the American Heart Association and the Heart Failure Society of America. It was created by 30 trainees spanning college through advanced fellowship under the leadership of CardioNerds Cofounders Dr. Amit Goyal and Dr. Dan Ambinder, with mentorship from Dr. Anu Lala, Dr. Robert Mentz, and Dr. Nancy Sweitzer. We thank Dr. Judy Bezanson and Dr. Elliott Antman for tremendous guidance.Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. American Heart Association's Scientific Sessions 2024As heard in this episode, the American Heart Association's Scientific Sessions 2024 is coming up November 16-18 in Chicago, Illinois at McCormick Place Convention Center. Come a day early for Pre-Sessions Symposia, Early Career content, QCOR programming and the International Symposium on November 15. It's a special year you won't want to miss for the premier event for advancements in cardiovascular science and medicine as AHA celebrates its 100th birthday. Registration is now open, secure your spot here!When registering, use code NERDS and if you're among the first 20 to sign up, you'll receive a free 1-year AHA Professional Membership! Question #37 Mr. S is an 80-year-old man with a history of hypertension, type II diabetes mellitus, and hypothyroidism who had an anterior myocardial infarction (MI) treated with a drug-eluting stent to the left anterior descending artery (LAD) 45 days ago. His course was complicated by a new LVEF reduction to 30%, and left bundle branch block (LBBB) with QRS duration of 152 ms in normal sinus rhythm. He reports he is feeling well and is able to enjoy gardening without symptoms, though he experiences dyspnea while walking to his bedroom on the second floor of his house. Repeat TTE shows persistent LVEF of 30% despite initiation of goal-directed medical therapy (GDMT). What is the best next step in his management?AMonitor for LVEF improvement for a total of 60 days prior to further interventionBImplantation of a dual-chamber ICDCImplantation of a CRT-DDContinue current management as device implantation is contraindicated given his advanced age Answer #37 Explanation Choice C is correct. Implantation of a CRT-D is the best next step. In patients with nonischemic DCM or ischemic heart disease at least 40 days post-MI with LVEF ≤35% and NYHA class II or III symptoms on chronic GDMT, who have reasonable expectation of meaningful survival for >1 year,ICD therapy is recommended for primary prevention of SCD to reduce total mortality (Class 1, LOE A). A transvenous ICD provides high economic value in this setting, particularly when a patient's risk of death from ventricular arrhythmia is deemed high and the risk of nonarrhythmic death is deemed low. In addition, for patients who have LVEF ≤35%, sinus rhythm, left bundle branch block (LBBB) with a QRS duration ≥150 ms, and NYHA class II, III, orambulatory IV symptoms on GDMT, cardiac resynchronization therapy (CRT) is indicated to reduce total mortality, reduce hospitalizations, and improve symptoms and QOL. Cardiac resynchronization provides high economic value in this setting. Mr.

This week we review a recent large scale study on catecholaminergic polymorphic ventricular tachycardia (CPVT) in children which is based on two large international registries. How do outcomes differ between those symptomatic CPVT patients treated with or without an ICD? Who amongst symptomatic CPVT pediatric patients likely warrant an ICD? What sort of ICD might be optimal - subcutaneous or transvenous? Are there ways to program ICD's in CPVT patients that may reduce inappropriate shocks? Why should the ICD be rarely employed in the CPVT pediatric patient? These are amongst the questions reviewed this week on the podcast. We speak with the work's senior author, Dr. Shubhayan Sanatani who is the chief of pediatric cardiology at BC Children's Hospital in Vancouver, British Columbia, Canada. doi: 10.1016/j.hrthm.2024.04.006. Epub 2024 Apr 7.

Reader feedback on cardiac devices and PFA, a new paradigm in the language of MI, sudden cardiac death, and measuring blood pressure are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Listener Feedback Sep 20, 2024 This Week in Cardiology Podcast https://www.medscape.com/viewarticle/1001631 Cardiac Devices https://www.acpjournals.org/doi/10.7326/ANNALS-24-00724 Impact of PFA on Intraluminal Esophageal Temperature https://onlinelibrary.wiley.com/doi/10.1111/jce.16096 II. Towards a New Classification of MI McLaren and colleagues; From STEMI to OMI https://doi.org/10.1016/j.jacadv.2024.101314 III. Sudden Death After MI. EHJ Paper; SCD After MI https://doi.org/10.1093/eurheartj/ehae326 Barsheshet and colleagues; Risk Score to Predict Benefit of ICD https://doi.org/10.1016/j.jacc.2012.02.036 Zegard and colleagues; Myocardial Fibrosis and SCD 10.1016/j.jacc.2020.10.046 MADIT RIT https://www.nejm.org/doi/full/10.1056/NEJMoa1211107 IV. BP Readings Poor Arm Position May Significantly Skew BP Readings https://www.medscape.com/viewarticle/poor-arm-position-may-significantly-skew-bp-readings-2024a1000icv?form=fpf ARMS Crossover RCT You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Revitalizing Your SCD is a bonus episode that was recorded live at the Area V meeting. We dove right into the heart of things discussing challenges with employee retention, overcoming difficulties, implementing conservation practices, and evolving to meet changing community needs. A key takeaway is that many SCD face similar challenges and it takes us all coming together and learning from one another to overcome those challenges. - Join SCD Supervisors Sean Weinert, Wes Frederickson, and Mike Olson along with NRCS employee Nikki Darrington and past SCD employee Camie Janikowski along with Area V Program Coordinator Hannah Nordby as they converse about serving, preserving, and conserving across the Great Plains. - It's More than Dirt that we talk about!

Building rapport with key stakeholders is vital in securing support and funds both locally and statewide. Join us to hear how SCDs can best tell their story to accomplish their conservation goals. - Join Representative Brandy Pyle, Lobbyist Kayla Effertz-Kleven, County Commissioner Stanley Dick along with County Commissioner and SCD employee Bob Flath, and Area V Program Coordinator Hannah Nordby as they converse about serving, preserving, and conserving across the Great Plains- AND beyond!   - It's More than Dirt that we talk about! 

In addition to her academic role, Dr. Ononogbu serves as a Board-Certified Hematology/Oncology Clinical Pharmacy Specialist at a Comprehensive Sickle Cell Center, where she provides specialized care and treatment for complex patient cases. Her clinical practice informs her research and offers practical solutions to improve patient outcomes in SCD care.Dr. Ononogbu is also deeply committed to mentoring future pharmacy leaders. She co-founded Pharmacy Initiative Leaders (PILs), a non-profit organization that helps pharmacy students secure post-doctoral residencies and fellowships, with a special emphasis on promoting diversity within the pharmacy workforce. A strong advocate for diversity, equity, and inclusion (DEI) in healthcare, Dr. Ononogbu is dedicated to ensuring equitable access to quality care, improving patient-provider communication, and fostering cultural competency in clinical settings. Her work continues to shape the future of pharmacy and improve care for those affected by sickle cell disease.Today's podcast is available to pharmacists and pharmacy technicians for CE credit and is worth 0.5 credits.To register for CE credit, please visit:https://www.lecturepanda.com/r/SCDOnDemand The objectives of today's podcast are:Discuss Sickle Cell Disease including pathophysiology as well as the history and timeline of SCD treatment.Interpret current challenges in SCD management and practical strategies to help improve care. Onye has no relevant financial relationships to disclose.

To recognize National Recovery Month, we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In episode 3, we speak with Kim MacDonald-Wilson, ScD, CPRP, senior director, Recovery and Wellness Transformation, and Tracy Carney, CPS, CPRP, senior recovery specialist, both at Community Care Behavioral Health Organization, part of the UPMC Insurance Services Division.

Two-time Emmy and Three-time NAACP Image Award-winning television Executive Producer Rushion McDonald interviewed Kier "Junior" Spates. Co-Host of Steve Harvey Morning Show and founded Kier's Hope to provide underprivileged individuals who suffer from Sickle Cell Disease to ensure they receive the medical, physical, and emotional attention they deserve. Suffering from sickle cell disease in silence is not uncommon in the African-American Community as there is a lack of knowledge of the disease. So, he created the Kier's Hope Foundation. The annual Kier's Hope 5K Fun Run and Walk and Junior Claus is an opportunity for families and those with sickle cell disease to gather and learn more about new treatments, spread awareness, and increase community engagement. Sickle Cell Disease is misunderstood as being contagious, an automatic death sentence, and that people with SCD can't do what "normal" people do!  Kier is changing that narrative. #AMI #BEST #SHMS  #STRAW  See omnystudio.com/listener for privacy information.

Two-time Emmy and Three-time NAACP Image Award-winning television Executive Producer Rushion McDonald interviewed Kier "Junior" Spates. Co-Host of Steve Harvey Morning Show and founded Kier's Hope to provide underprivileged individuals who suffer from Sickle Cell Disease to ensure they receive the medical, physical, and emotional attention they deserve. Suffering from sickle cell disease in silence is not uncommon in the African-American Community as there is a lack of knowledge of the disease. So, he created the Kier's Hope Foundation. The annual Kier's Hope 5K Fun Run and Walk and Junior Claus is an opportunity for families and those with sickle cell disease to gather and learn more about new treatments, spread awareness, and increase community engagement. Sickle Cell Disease is misunderstood as being contagious, an automatic death sentence, and that people with SCD can't do what "normal" people do!  Kier is changing that narrative. #AMI #BEST #SHMS  #STRAW  Support the show: https://www.steveharveyfm.com/See omnystudio.com/listener for privacy information.

Two-time Emmy and Three-time NAACP Image Award-winning television Executive Producer Rushion McDonald interviewed Kier "Junior" Spates. Co-Host of Steve Harvey Morning Show and founded Kier's Hope to provide underprivileged individuals who suffer from Sickle Cell Disease to ensure they receive the medical, physical, and emotional attention they deserve. Suffering from sickle cell disease in silence is not uncommon in the African-American Community as there is a lack of knowledge of the disease. So, he created the Kier's Hope Foundation. The annual Kier's Hope 5K Fun Run and Walk and Junior Claus is an opportunity for families and those with sickle cell disease to gather and learn more about new treatments, spread awareness, and increase community engagement. Sickle Cell Disease is misunderstood as being contagious, an automatic death sentence, and that people with SCD can't do what "normal" people do!  Kier is changing that narrative. #AMI #BEST #SHMS  #STRAW  See omnystudio.com/listener for privacy information.

Two-time Emmy and Three-time NAACP Image Award-winning television Executive Producer Rushion McDonald interviewed Kier "Junior" Spates. Co-Host of Steve Harvey Morning Show and founded Kier's Hope to provide underprivileged individuals who suffer from Sickle Cell Disease to ensure they receive the medical, physical, and emotional attention they deserve. Suffering from sickle cell disease in silence is not uncommon in the African-American Community as there is a lack of knowledge of the disease. So, he created the Kier's Hope Foundation. The annual Kier's Hope 5K Fun Run and Walk and Junior Claus is an opportunity for families and those with sickle cell disease to gather and learn more about new treatments, spread awareness, and increase community engagement. Sickle Cell Disease is misunderstood as being contagious, an automatic death sentence, and that people with SCD can't do what "normal" people do!  Kier is changing that narrative. #AMI #BEST #SHMS  #STRAW  See omnystudio.com/listener for privacy information.

Suicidal ideation and GLP-1 agonists, a repeat of PARADIGM HF in Chagas CM, CASTLE HTx critical appraisal, and primary prevention of SCD in HF are the topics John Mandrola, MD, covers this week. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I. Suicidal ideation with GLP-1 Signal of Suicidality With GLP-1 RA Semaglutide, but Experts Urge Caution https://www.medscape.com/viewarticle/signal-suicidality-glp-1-ra-semaglutide-experts-urge-caution-2024a1000fa7 Disproportionality Analysis from World Health Organization Data on Semaglutide, Liraglutide, and Suicidality   Variability in Disproportionality paper https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2021.668765/full II. PARACHUTE HF: Repeating the Mistakes in PARADIGM HF PARACHUTE HF https://www.jacc.org/doi/10.1016/j.jchf.2024.05.021 SOLVD https://www.nejm.org/doi/full/10.1056/NEJM199108013250501 CONSENSUS trial https://www.nejm.org/doi/full/10.1056/NEJM198706043162301 Meta-analysis of Low vs High Dose ACE/ARB https://doi.org/10.1161/CIRCHEARTFAILURE.117.003956 Meta-analysis of Sac/Val vs ARB/ACE Inhibitors https://link.springer.com/article/10.1007/s00228-024-03686-6 PARADISE MI https://www.nejm.org/doi/full/10.1056/NEJMoa2104508 III. CASTLE HTx Critical Appraisal Critical Appraisal of CASTLE HTx https://doi.org/10.1016/j.jacc.2024.06.020 CASTLE HTx https://www.nejm.org/doi/10.1056/NEJMoa2306037 CASTLE AF https://www.nejm.org/doi/full/10.1056/NEJMoa1707855 IV. More Data Suggesting Modest Benefits of the Primary Prevention ICD First and Recurrent ICD Shocks: JICE Paper from Denmark https://link.springer.com/article/10.1007/s10840-024-01873-0 HF trialists https://www.nejm.org/doi/full/10.1056/NEJMoa1609758 PROFID Trial https://profid-project.eu/ DANISH  https://www.nejm.org/doi/full/10.1056/NEJMoa1608029 SCD-HeFT https://www.nejm.org/doi/full/10.1056/NEJMoa043399 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

In this week's episode, we discuss the management of sickle cell disease in the chronic setting. This is a follow up to episode 111 where we discussed acute management of SCD. And furthermore, this is also in addition to our prior discussion about long-term chronic complications from SCD in episode 110. We highly recommend checking out these prior episodes if you haven't done so already!Contents: - Use of hydroxyurea in SCD management- Newer adjunctive therapies for SCD management - Perioperative management ****Have some time and want to make some extra money? Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

In this week's episode, we discuss chronic complications that can arise in patients with sickle cell disease. The reality is, that unless we have an outpatient clinic or rotate through an outpatient clinic, there is a small chance that we will come across many of these issues. However, screening for and managing these chronic complications can have significant implications on our patients' lives. Contents: - What are the current screening guidelines for sickle cell disease complications?- What are key studies in pediatric SCD management? - Management of stroke, avascular necrosis, pain, pulmonary hypertension, kidney disease, iron overload, and other important complications to be aware of **Have some time and want to make some extra money? Get paid to participate in market research surveys: https://affiliatepanel.members-only.online/FOC_24?utm_campaign=FOC&utm_source=email&utm_medium=email ** Want to review the show notes for this episode and others? Check out our website: https://www.thefellowoncall.com/our-episodesLove what you hear? Tell a friend and leave a review on our podcast streaming platforms!Twitter: @TheFellowOnCallInstagram: @TheFellowOnCallListen in on: Apple Podcast, Spotify, and Google Podcast

Oxalates are naturally occurring substances found in many plants, including vegetables, fruits, nuts and seeds. Ruth Ann Foster, ScD, BSN, RN discusses oxalates and explore the underlying causes of that gut dysfunction and how it relates to overall health.